The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite COL not yet being used clinically for cancer therapy because of its toxicity to normal cells, it is used as a lead compound in generating potent anticancer agents [5,6,7,8,9].”
From Targeted Nano-Drug Delivery of Colchicine against Colon Cancer Cells by Means of Mesoporous Silica Nanoparticles (2020) · cites this paper as [7]
In the citing paper
“Several reports have demonstrated that COL can arrest at G2/M in different cancer cells [7,56].”
From Targeted Nano-Drug Delivery of Colchicine against Colon Cancer Cells by Means of Mesoporous Silica Nanoparticles (2020) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Flagged first, then by citations
Research works printed but not linked: 23
- Czajkowski, 2015, Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy, Biomed Res Int, 2015, 851387
- Schwartz, 2015, Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors, Invest New Drugs, 33, 349, 10.1007/s10637-014-0191-5 · DOI
- Cohen, 2015, The discovery and development of sorafenib for the treatment of thyroid cancer, Expert Opin Drug Discov, 10, 427, 10.1517/17460441.2015.1006194 · DOI
- Gurski, 2015, Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations, Cancer Discov, 5, 358, 10.1158/2159-8290.CD-14-1518 · DOI · Paper page
- Tetzlaff, 2014, Systematic identification of signaling pathways with potential to confer anticancer drug resistance, Sci Signal, 7, ra121, 10.1126/scisignal.aaa1877 · DOI
- Adams, 2015, BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model, Proc Natl Acad Sci U S A, 112, E536, 10.1073/pnas.1418163112 · DOI
- Colevas, 2015, Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients, Oncologist, 20, 113, 10.1634/theoncologist.2014-0313 · DOI
- Fagin, 2003, High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma, Cancer Res, 63, 1454
- Asa, 2006, Pathogenetic mechanisms in thyroid follicular-cell neoplasia, Nat Rev Cancer, 6, 292, 10.1038/nrc1836 · DOI
- Nucera, 2015, Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations, J Clin Endocrinol Metab, 100, 35, 10.1210/jc.2014-2803 · DOI
- Cancer Genome Atlas Research N, 2014, Integrated genomic characterization of papillary thyroid carcinoma, Cell, 159, 676, 10.1016/j.cell.2014.09.050 · DOI
- Sobrinho-Simoes, 2014, Prognostic biomarkers in thyroid cancer, Virchows Arch, 464, 333, 10.1007/s00428-013-1521-2 · DOI
- Colombo, 2016, Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants, J Clin Endocrinol Metab, 101, 264, 10.1210/jc.2015-2917 · DOI
- Dhar, 2014, Tubulin inhibitors: a patent survey, Recent Pat Anticancer Drug Discov, 9, 176, 10.2174/15748928113089990042 · DOI
- Falchook, 2015, BRAF inhibitors: experience in thyroid cancer and general review of toxicity, Horm Cancer, 6, 21, 10.1007/s12672-014-0207-9 · DOI
- Austin, 2008, Quantitative high-throughput screening using a live-cell cAMP assay identifies small-molecule agonists of the TSH receptor, J Biomol Screen, 13, 120, 10.1177/1087057107313786 · DOI
- Li, 2015, Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer, Oncotarget, 6, 9073, 10.18632/oncotarget.3268 · DOI
- Rozanski, 2013, Tubulin-interactive stilbene derivatives as anticancer agents, Cell Mol Biol Lett, 18, 368
- Ethiraj, 2015, Tubulins - the target for anticancer therapy, Curr Top Med Chem, 15, 73, 10.2174/1568026615666150112115805 · DOI
- Kraus, 2015, Colchicine-Update on mechanisms of action and therapeutic uses, Semin Arthritis Rheum, 45, 341, 10.1016/j.semarthrit.2015.06.013 · DOI
- Lin, 2015, S100A8 is a novel therapeutic target for anaplastic thyroid carcinoma, J Clin Endocrinol Metab, 100, E232, 10.1210/jc.2014-2988 · DOI
- Chen, 2007, p38 and JNK MAPK, but not ERK1/2 MAPK, play important role in colchicine-induced cortical neurons apoptosis, Eur J Pharmacol, 576, 26, 10.1016/j.ejphar.2007.07.067 · DOI
- Pandey, 2014, Novel analogue of colchicine induces selective pro-death autophagy and necrosis in human cancer cells, PLoS One, 9, e87064, 10.1371/journal.pone.0087064 · DOI
Cited by
Sorted by citations
AbouAitah, K., Hassan, H. A., Swiderska-Sroda, A., Gohar, L., Shaker, O. G., Wojnarowicz, J., Opalinska, A., Smalc-Koziorowska, J., Gierlotka, S., & Lojkowski, W. (2020) · Cancers · doi:10.3390/cancers12010144 · Cited by 105
Metadata
- Authors
- Zhang, L., Yang, Z., Granieri, L., Pasculescu, A., Datti, A., Asa, S. L., Xu, Z., & Ezzat, S.
- Affiliations
- Department of Breast Surgery, China-Japan Union Hospital, Jilin University, Changchun, Jilin, P.R. China
- SMART Laboratory for High-Throughput Screening Programs, Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Toronto, ON, Canada
- Ontario Cancer Institute and The Endocrine Oncology Site Group, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-03-03
- Volume
- 7
- Issue
- 15
- Pages
- 19948-19959
- ISSN
- 1949-2553
- PMC
- PMC4991430
- Cited by
- 16
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
